Multiple Myeloma Clinical Trial Closes Early Due To Superior Results Of Comparative Treatment

April 11, 2007 – 3:01 pm | posted in Blood / Hematology, Cancer / Oncology, Clinical Trials / Drug Trials

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.

The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had a one-year survival rate of 86 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 96.5 percent overall survival rate at one year, with much less toxicity.

“In my opinion, this is the best one-year survival data that I’ve seen in a large phase 3 study in myeloma,” says Vincent Rajkumar, M.D., Mayo Clinic hematologist and primary investigator of the ECOG study. “This is a major advance in the treatment of this cancer.”

All patients on the high-dose dexamethasone arm of the clinical trial will be moved to the low-dose arm. A successor study using lenalidomide plus high-dose dexamethasone was closed early as a result of these findings.

Mayo Clinic
200 First St. SW
Rochester, MN 55902
United States
http://www.mayoclinic.com/

ShareThis

Also Read

  • Multiple Myeloma Clinical Trial Closes Early
  • Drug Combination Slows Progression Of Treatment Resistant Bone Marrow Cancer
  • Drug Combination Proves Effective Against Myeloma In Phase I Trial
  • Mold By-product Kills Multiple Myeloma
  • The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
  • Signaling Protein For Multiple Myeloma Identified, Findings May Result In New Therapeutic Target
  • Mayo Clinic — Collaborating To Move Treatment Research Forward
  • Velcura Therapeutics, Inc. Reports Positive Pre IND Meeting With FDA And Plans Early Clinical Trials To Treat Multiple Myeloma Bone Disease
  • The Multiple Myeloma Research Consortium And Nereus Pharmaceuticals Initiate Clinical Trial Investigating NPI-0052 To Treat Multiple Myeloma
  • Sunesis Presents Data Supporting SNS-032’s Potential Anticancer Activity In Multiple Myeloma At The American Association For Cancer Research Meeting

    • You must be logged in to post a comment.